Repligen Corporation (‘Repligen’), a global life sciences company, develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
The company’s primary customers – global biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies (integrators) – are vital to its operations.
The company is committed to inspiring advances in b...
Repligen Corporation (‘Repligen’), a global life sciences company, develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
The company’s primary customers – global biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies (integrators) – are vital to its operations.
The company is committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies (‘mAbs’), mAb derivatives, recombinant proteins, RNA-based therapeutics and vaccines, and cell and gene therapies (‘C>’) – that are improving human health worldwide. Increasingly, the company’s technologies are being implemented to overcome challenges in processing plasmid DNA (a starting material for the production of mRNA) and gene delivery vectors, such as lentivirus and adeno-associated viral vectors.
The company operates as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. A majority of the company’s 16 manufacturing sites are located in the United States (California, Massachusetts, New Hampshire, New Jersey, and New York). Outside the United States, it has manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan.
Products
The company’s bioprocessing business consists of four main franchises: Filtration (including Fluid Management), Chromatography, Process Analytics, and Proteins.
Since 2012, the company has purposely built a highly diversified portfolio of products offered under these franchises, developing high-value technologies that enable more efficient drug manufacturing processes for its customers through internal research and development (‘R&D’) programs and strategic acquisitions. The company is committed to sustainable innovation and has earned a reputation as an innovation leader in bioprocessing. It has consistently introduced disruptive new products that solve specific bioprocessing challenges faced by its customers. The company’s growth strategy continues to expand its geographic scope and customer base, and broaden the applications of its technologies.
To support the company’s sales goals for these products, it makes ongoing investments in its commercial organization, its R&D programs, its business systems, and its manufacturing capacity. The company regularly evaluates and invests in these areas as needed to ensure timely deliveries and to stay ahead of customer demand for its products.
The majority of the company’s revenue is derived from consumable and/or single-campaign (‘single-use’) product sales, as compared to associated hardware and equipment. The customization, scalability and plug-and-play convenience of these products, and in many cases the closed nature of the company’s technologies, make them ideal for use in biologics manufacturing processes where contamination risk is a critical concern of its customers.
Shifting to Integrated Solutions
Since 2012, and through year-end 2024, the company has completed 14 acquisitions across its four franchises, building a base of technology assets that it can improve upon and/or develop next-generation versions of through its internal R&D team. The company’s acquisition strategy is purposeful, considering the potential for integration with its internally developed technologies, and across products and franchises.
In 2024, the results of the company’s mergers and acquisitions and R&D efforts are reflected in its ability to offer more integrated solutions across the bioproduction workflow. The company’s commercial approach is shifting from ‘individual product’ to ‘whole system’ sales that can support entire unit operations, the management of fluids between unit operations, and in-line advanced analytics. For example, providing filtration systems for production and harvest steps (upstream), and connecting those to chromatography and filtration systems for purification and formulation steps (downstream).
Key Products Within Each of the company’s Franchises
Filtration
Filtration is the company’s largest franchise with the broadest product offering covering upstream and downstream technologies. Below is a description of some of its key products:
XCell ATF Cell Retention Systems
The company’s filtration products offer a number of advantages to manufacturers of biologic drugs and are used in process development and process scale (clinical and commercial) production. The company’s XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing.
XCell ATF is a cell retention technology. The system consists of an advanced hollow fiber (‘HF’) filtration device, a low shear pump, and a controller. The XCell ATF system is connected to a bioreactor and enables the cell culture to be run continuously, with cells being retained in the bioreactor, fresh nutrients (cell culture media) being fed into the reactor continuously, and clarified biological product and cell waste being removed (harvested) continuously. The cells are maintained in a consistent nutrient-rich environment and can reach cell densities two- and three-times higher than those achieved by standard fed-batch culture. As a result, product yield is increased, which improves facility utilization and can reduce the size of a bioreactor required to manufacture a given volume of biologic drug product. XCell ATF systems are available in a wide range of sizes that can easily scale from laboratory use through full production with bioreactors as large as 5,000 liters.
In 2023, the company introduced next-generation XCell Large-Scale controllers, enabling increased process intensification through dual-operation of two ATF devices from a single controller, and through advanced monitoring and control of flow rates with smart sensor technology. The company’s ATF large-scale controllers are designed for scalability from bench top to commercial manufacturing, and for versatility of applications, including perfusion and modified fed-batch (N-1) manufacturing.
Tangential Flow Filtration Consumables
The company’s TangenX product portfolio includes flat sheet (‘FS’) tangential flow filtration (‘TFF’) cassettes that are used primarily in downstream, ultrafiltration processes, e.g., biologic drug concentration, buffer exchange, and formulation processes. The company’s single-use SIUS line, including its reusable PRO line of cassettes, providing customers with a high-performance, cost-saving alternative to other companies' TFF cassette offerings and its TangenX SC Device, the industry's first holder-free, self-contained (‘SC’) TFF device, which was launched in November 2023.
The company’s TangenX FS TFF cassettes feature high performing-membrane chemistries that offer superior selectivity for a wide range of applications. A controlled manufacturing process that balances flux and selectivity delivers maximum flux for increased productivity and tight control of the membrane pore size for enhanced selectivity and recovery. Each single-use cassette is delivered pre-sanitized and ready to be equilibrated and used for tangential flow, ultrafiltration, and diafiltration applications.
The use of SIUS TFF cassettes eliminates non-value-added steps (cleaning, testing between uses, storage, and flushing) that are required with reusable TFF products, providing cost and time savings. For process economics requiring reusable cassettes, TangenX PRO cassettes are available with the same high-performance membranes used in SIUS cassettes. The company’s TangenX cassettes are interchangeable with filter hardware from multiple manufacturers, simplifying customer trial and adoption. In 2020, the company introduced the SIUS Gamma single-use device, which it engineered to harness the performance and efficiencies of TangenX SIUS membranes and cassettes, while also providing the convenience of a fully assembled, aseptically closed, and gamma-irradiated, sterile device. The device is delivered as a single unit composed of the cassette, fluid manifold, clamps, tubing, and aseptic connectors. The SIUS Gamma device is ideal for adenovirus C> and other processes where large volumes need to be concentrated in a sterile, closed environment.
The company’s TangenX SC Device simplifies and streamlines downstream flat sheet UF/DF processes by reducing setup time by 80%, eliminating holders and torquing requirements, which reduces the risk of product loss caused by changes in compression or cassette misalignment during installation, allowing users to seamlessly transition from traditional cassettes and reducing bioburden risk, as well as enhancing safety because it is aseptically closed and gamma irradiated and isolates operators from potentially hazardous materials.
Tangential Flow Filtration Systems: KrosFlo TFF
The company’s KrosFlo systems for TFF combine significant configurability with premium quality manufacturing. The company’s TFF systems are designed for scalability from small to large (up to 5,000 liters) volumes, flexibility between HF and FS filter formats, and the ability to use the same system in different unit operations while deploying ready-to-use application-specific flow paths.
The company’s KrosFlo TFF systems are turnkey solutions for TFF, offered with either TangenX FS cassettes or with its HF filters.
KrosFlo Flat Sheet TFF Systems
The company’s 2020 acquisition of ARTeSYN Biosolutions Holdings Ireland Limited (‘ARTeSYN’) enabled it to develop and market KrosFlo RS TFF systems that integrate the company’s consumable and equipment offerings, providing greater convenience and efficiency for its customers.
The company launched its KrosFlo RS 20 series systems in 2022, focusing their use in mRNA and cell and gene therapies (‘C>’) therapy applications, where they are used primarily in downstream formulation. These responsive TFF systems completely automate sanitization, concentration, and product recovery processes. The combination of injection molded tubing, over-molded connectors, and valve blocks significantly lowers product hold-up volume to maximize product recovery. With the same software, hardware, controls, and cGMP compliance built into every system, and with pre-assembled flow kits for error-free installation, the KrosFlo RS platform offers operational simplicity that can easily be scalable from lab- through production-scale use. KrosFlo FS systems integrate over 10 components with specifications to process volumes between 140 milliliters and 500 liters.
KrosFlo Hollow Fiber TFF Systems
The company’s filtration business is strengthened by a leading portfolio of Spectrum HF filtration solutions, including fully integrated KrosFlo TFF systems with Konduit automated process monitoring and ProConnex Flow Path single-use assemblies. The KrosFlo family of HF TFF systems integrates multiple components with specifications to process volumes between 2 milliliters and 5,000 liters – from lab-scale through commercial manufacturing.
In early 2023, the company introduced its RS 30 series of KrosFlo TFF systems, featuring increased automation capabilities. The RS 30 series systems integrate a single-use tulip tank re-circulation vessel, which allows for dynamic control and response to changing fluid levels for maximum product recovery in fed-batch, batch concentration, and diafiltration processes. The cGMP compliant, fully automated 1/2 inch single-use TFF system delivers outstanding performance in a small footprint. In alignment with its integrated systems strategy, the system includes ProConnex flow paths to integrate advanced fluid management technologies, including overmolded connections, pump heads, tubing filters, and sensors in a single-use device. Flow paths easily attach to the system to simplify operation and increase process efficiency.
KrosFlo RPM Systems with Integrated CTech FlowVPX Technology
In 2022, the company completed the development of a hollow fiber system that combines KrosFlo TFF with CTech FlowVPX Real-Time Process Management (‘RPM’) technology, enabling ‘walk-away automation’ of downstream UF/DF processes. Toward the end of 2022, the company launched KrosFlo KR2i RPM for low-volume, high concentration applications. This was the first-to-market TFF system to incorporate real-time process monitoring for in-line protein concentration management. By coupling KrosFlo TFF and FlowVPX functionality, customers can benefit from improved process control and efficiency, while reducing process risk by ensuring accurate concentration throughout the TFF process.
KrosFlo RPM systems monitor concentration during UF/DF runs without having to depend on mass inputs and off-line fixed pathlength UV-Vis spectrophotometers. Risk is further mitigated with fully enclosed ProConnex custom flow paths as a part of the automated TFF process.
Since the debut of the KrosFlo KR2i RPM (2 mL-15L) system, the company expanded the KrosFlo RPM offering, introducing KrosFlo FS-15 RPM (150mL-15L) toward the end of 2023. In 2024, the company introduced KrosFlo RS-10 – the first bench-scale TFF system built specifically for cGMP production, with end-to-end automation.
The KrosFlo RPM Systems portfolio continues to expand to cover a wide range of volumes from lab-to production-scale requirements.
Tangential Flow Depth Filtration Systems: KrosFlo TFDF
The company’s KrosFlo TFDF systems are a unique technology that combines the benefits of both tangential flow and depth filtration, simplifying and intensifying upstream perfusion for viral vector production for Cell and Gene Therapy. Combining advanced control hardware, novel high-throughput tubular depth filters, and ProConnex TFDF flow paths, the system offers high flux, superior capacity, and low turbidity. Integrated sensors streamline validation, while low hold-up volume, high recovery, and a small footprint reduce processing time and simplify setup. TFDF technology provides a scalable, efficient technology to increase viral vector production.
Strengthening the company’s Filtration Franchise through Acquisitions
With the company’s acquisition of Polymem S.A. (‘Polymem’) on July 1, 2021, the company further expanded its HF membrane and module production capabilities and added core R&D, engineering, and production expertise in HF technology for both industrial and bioprocessing markets. The Polymem business complements its Spectrum HF product line, which includes KrosFlo HF TFF systems and ProConnex fluid management. The acquisition of Polymem accelerated its HF manufacturing buildout and added a Europe-based HF manufacturing center of excellence.
With the company’s acquisition of BioFlex Solutions LLC (‘BioFlex’) and Newton T&M Corp. (‘NTM’) on December 16, 2021, it complemented and expanded its filtration franchise, as both BioFlex and NTM focus on single-use fluid management components, including single-use clamps, adapters, end caps, and hose assemblies. These products are essential components in its upstream and downstream product offerings – especially its systems with line-sets and flow paths. These acquisitions streamline and increase its control over many components in its single-use supply chain, which ultimately should drive reduced lead times for its customers in the coming years.
The company acquired FlexBiosys, Inc. (‘FlexBiosys’) on April 17, 2023, further complementing and expanding its fluid management portfolio of offerings with its expert design and custom manufacturing of single-use bioprocessing products and a comprehensive range of products that include bioprocessing bags, bottles, and tubing assemblies.
With the company’s acquisition of Metenova Holding AB (‘Metenova’) on October 2, 2023, it strengthened its fluid management portfolio with the addition of magnetic mixing and drive train technologies that are widely used by global biopharmaceutical companies and contract development and manufacturing organizations.
The growth of the company’s filtration business has allowed it to substantially increase its direct sales presence in Europe and Asia and diversify its end markets to include all biologic classes, including mAbs, vaccines, recombinant proteins, and C>.
Chromatography
The company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing, and quality control of biological drugs. The main driver of growth in this portfolio is its OPUS pre-packed column (‘PPC’) product line.
In addition to OPUS, with the company’s acquisition of ARTeSYN in 2020, it added chromatography systems to its offerings, providing greater flexibility and market opportunity as it scales and expands its systems portfolio.
Additional chromatography products include the company’s ELISA test kits, used by quality control departments to detect and measure the presence of leached Protein A and/or growth factor in the final product. The company’s chromatography ligand and resin products are part of its Proteins portfolio.
OPUS Pre-Packed Columns
The company’s chromatography franchise features a wide range of OPUS columns, which it delivers to its customers sealed and pre-packed with their choice of resin. These are single-use or campaign-use disposable columns that replace the use of customer-packed glass columns for downstream purification. By designing OPUS columns to be a technologically advanced and flexible option for the purification of biologics from process development through clinical and commercial-scale manufacturing, the company has become a leader in the PPC market.
The company launched its first production-scale OPUS columns in 2012 and has since added larger diameter options that scale up to use with 2,000 liter bioreactors. The company’s OPUS 80R column is the largest available PPC on the market for use in late-stage clinical or commercial purification processes. It offers unique features, such as a resin recovery port on its larger columns, which allows its customers to remove and reuse the recovered resin in other applications.
In addition to the company’s larger scale OPUS columns, its portfolio includes its smaller-scale OPUS columns, including its RoboColumn, MiniChrom, and ValiChrom columns used for process development (‘PD’) and validation. These columns are used in high-throughput PD screening, viral clearance validation studies, and scale-down validation of chromatography processes.
The company maintains customer-facing and manufacturing centers in both the United States and Europe for its OPUS column customers and offers a premier ability to pack any of hundreds of chromatography capture resins available, as per the company’s customers’ choice.
KRM Chromatography Systems
Through the company’s acquisition of ARTeSYN in 2020, it gained state-of-the-art, configurable chromatography systems that can integrate a wide range of hardware, components, and consumable products to simplify bioprocessing operations for its customers. The company’s KRM chromatography systems are precision engineered for high product recovery (low hold-up volumes), high bioactivity (less stress on the product of interest), and reduced risk of deviation (simple changeovers and pre-assembled flow kits). The KRM systems contain closed single-use flow paths (less risk of contamination and product loss) and other advanced fluid management technologies, including over-molded connectors, pump heads, filters, and pressure sensors, as well as intuitive software and its process analytics technology enabled.
Process Analytics
The company’s process analytics products complement and support its filtration, chromatography, and proteins franchises, as they allow end-users to make at-line or in-line absorbance measurements, allowing for the determination of protein concentration in filtration, chromatography formulation, and fill-finish applications.
SoloVPE Device
The company’s SoloVPE slope spectroscopy system is the industry standard for offline and at-line absorbance measurements for protein concentration determination in process development, manufacturing, and quality control settings.
FlowVPE Device
The company’s FlowVPE slope spectroscopy system enhances the power of slope spectroscopy and provides in-line protein concentration measurement for filtration, chromatography, and fill-finish applications. A key benefit of this in-line solution is the ability to monitor a manufacturing process in real time.
FlowVPX System
The FlowVPX slope spectroscopy system is its next-generation FlowVPE, launched at the beginning of 2021 and designed to meet the rigors of regulatory GMP requirements. FlowVPX offers reliable real-time results with integrated ease for concentration measurements during every stage of the downstream GMP-compliant production-scale biologics manufacturing.
The use of slope spectroscopy systems delivers multiple process benefits for the company’s biopharmaceutical manufacturing customers, compared to traditional UV-Vis approaches. Key benefits include: the elimination of manual dilutions and sample transfers from process development/manufacturing to labs, rapid time to results (minutes versus hours), improved precision, built-in data quality for improved reporting and validation, and ease of use.
KrosFlo RPM Systems with Integrated FlowVPX Technology
In 2022, the company completed the development of a hollow fiber system that combines KrosFlo TFF with CTech FlowVPX Real-Time Process Management (‘RPM’) technology, enabling ‘walk-away automation’ of downstream UF/DF processes.
Culpeo QCL-IR Liquid Analyzer
Pursuant to a 15-year license agreement that the company entered into with DRS Daylight Solutions, Inc. (‘Daylight’) in September 2022, it obtained the exclusive right to use Daylight's quantum cascade laser technology (‘QCL’), including its Culpeo QCL-IR Liquid Analyzer (‘Culpeo’), specifically in the field of bioprocessing. In November 2024, the company amended the Daylight license agreement to extend the License Agreement one additional year. Culpeo is a compact, intelligent spectrometer that uses the power of QCL to analyze and identify chemicals. The company’s in-licensing of these rights complements its existing process analytics franchise. Additionally, the company is focused on expanding the QCL portfolio, with plans to integrate these solutions into its chromatography and filtration systems.
Proteins
The company’s proteins franchise is represented by its affinity ligands and resins used to purify a wide range of biological drugs, including monoclonal antibodies and new modalities. The company’s proteins franchise also includes cell culture growth factor products, which are a key component of cell culture media used in upstream bioprocessing to increase cell density and improve product yield.
Protein A Affinity Ligands
Protein A ligands are the essential ‘binding’ component of Protein A affinity chromatography resins used in the purification of virtually all mAb-based drugs on the market or in development. Historically, the company manufactured multiple forms of Protein A ligands under long-term supply agreements with major life sciences companies, including Cytiva (a standalone operating company owned by Danaher Corporation), MilliporeSigma, and Ecolab Life Sciences (‘Ecolab’) for their Purolite (‘Purolite’) resin business. These life sciences companies, in turn, sell their chromatography resins to end users (pharmaceutical developers and manufacturers). Cytiva has fully transitioned to in-house manufacturing for its ligand needs; however, the company continues to manufacture its ligands for integrators, including Purolite.
Affinity Ligand Collaborations
In June 2018, the company entered into an agreement with Navigo Proteins GmbH (‘Navigo’) for the exclusive co-development of multiple affinity ligands for which the company holds commercialization rights. It manufactures and exclusively supplies the first of these ligands, NGL-Impact A, to Purolite, for use with their Purolite Praesto Jetted A50 Protein A resin product.
In September 2021, the company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The company is manufacturing and supplying this ligand, NGL-Impact HipH, to Purolite. It has a long-term supply agreement with Purolite for NGL-Impact and potential additional affinity ligands that may advance from its Navigo collaboration.
Purolite Agreement
In October 2022, the company extended its long-term supply agreement with Purolite through 2032 and broadened its scope to include affinity ligands targeting antibody fragments in addition to those targeting mAbs and Fc-fusion proteins. This extension and product line expansion align with its Proteins strategy and support the acceleration in market adoption of the Praesto affinity resin portfolio. It provides Purolite with exclusive access to mAb fragment ligands developed at Avitide, Inc. (‘Avitide’), in addition to the NGL portfolio developed at Navigo. The company will continue to receive access to Purolite's leading-edge base bead technology, as it proceeds with the development and commercialization of novel affinity resins focused on new modalities and C>.
In 2024, the company and Ecolab announced the commercial launch of Praesto CH1, a cross-linked agarose-based affinity resin designed to purify specialized mAbs, such as bispecific antibodies and recombinant antibody fragments. This resin utilizes mAb fragment ligands developed at Avitide and provides an alternative for the purification of antibody variants when Protein A resins are not suitable.
Adeno-Associated Virus Affinity Ligands and Resins from Avitide
In September 2021, the company completed its strategic acquisition of Avitide, a market leader in affinity ligand discovery and development. This acquisition was a major step forward in building its proteins franchise, moving the company into affinity resin solutions for C> and other emerging modalities.
In February 2022, the company launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins AVIPure-AAV9, AVIPure-AAV8, and AVIPure-AAV2 were developed by Avitide and are specific to the major adeno-associated virus (‘AAV’) C> vectors used today. AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. In 2023, a new affinity resin for AAV5 was also launched, expanding the portfolio.
With the company’s acquisition of Tantti Laboratory Inc. (‘Tantti’) on December 2, 2024, it expects to accelerate its expansion into new modality markets with unique, scalable purification solutions for these larger molecule biologics.
In December 2024, the company launched AviPure dsRNA Clear resin, pre-packed in OPUS columns. The AVIPure dsRNA Clear resin combines Avitide proprietary affinity ligands with Tantti’s Dulocore base bead technology to improve the purification of mRNA therapeutics and vaccines. This is double-stranded RNA resin, the first affinity resin to remove the double-stranded RNA impurity from transcribed RNA without heat or solvents.
Growth Factors
Most biopharmaceuticals are produced through an upstream mammalian cell culture process. In order to stimulate increased cell growth and maximize overall yield from a bioreactor, manufacturers often add growth factors, such as insulin, to their cell culture media. The company’s cell culture growth factor additives include LONG R3 IGF 1, its insulin-like growth factor that has been shown to be up to 100 times more biologically potent than insulin (the industry standard), thereby increasing recombinant protein production in cell culture fermentation applications.
2024 Acquisition
Tantti Laboratory Inc.
On December 2, 2024, the company's subsidiary, Repligen Sweden AB, acquired Tantti Laboratory Inc. (‘Tantti’) from the former shareholders of Tantti (‘Tantti Seller’) pursuant to a share swap agreement, dated as of July 27, 2024 (such acquisition, the ‘Tantti Acquisition’), by and among Repligen Sweden AB, the Tantti Seller, and the company, in its capacity as guarantor of the obligations of Repligen Sweden AB under the Share Purchase Agreement.
Strategy
The company is focused on the development, production, and commercialization of highly differentiated, technology-leading systems and solutions that address specific pressure points in the biologics manufacturing process and deliver substantial value to its customers. The company’s products are designed to optimize its customers’ workflow to maximize productivity, and the company is committed to supporting its customers with strong customer service and applications expertise.
The company’s strategies are continued innovation, platforming its products, targeted acquisitions, and geographical expansion.
Sales and Marketing
The company’s sales and marketing strategy supports its objective of strengthening its position as a leading provider of products and services, addressing upstream, downstream, and quality control needs of bioprocessing customers in the biopharmaceutical industry.
Ligand Supply Agreements
For the company’s proteins franchise, it is committed to being a partner of choice for its customers with distributor and supply agreements in place with large life sciences companies, such as Cytiva, MilliporeSigma, and Purolite. The Cytiva Protein A supply agreement relating to its Waltham, Massachusetts facility was amended in September 2021 and, pursuant to its amended terms, runs through 2025. The company’s Protein A amended supply agreement with Purolite was amended in October 2022 and, pursuant to its amended terms, runs through 2032. The company’s dual manufacturing capability provides strong business continuity and reduces overall supply risk for its ligand customers.
Significant Customers and Geographic Reporting
Customers for the company’s bioprocessing products include major life sciences companies, contract manufacturing organizations, biopharmaceutical companies, diagnostics companies, and laboratory researchers.
Intellectual Property
The company owns or has exclusive rights to at least 207 active patent grants and 142 pending patent applications in the United States and other foreign jurisdictions, including Australia, Canada, China, France, Germany, India, Japan, South Korea, Sweden, and the United Kingdom.
Filtration
For the company’s filtration franchise, its patent grants include coverage for ATF filtration, TFDF, and TFF HF and FS systems, membranes, filters, mixers, flow paths, and single-use technologies. The company continually seeks to improve upon these technologies and has multiple new patent filings, including patents covering next-generation TFDF filters, next-generation ATF filtration technologies, and proprietary reduced-cost system components.
Chromatography
The company’s patent grants include coverage for certain unique methods and features of its OPUS PPC, including methods of manufacturing column components, systems for removing air using specialized tubing and valve systems, medium recovery systems, methods for packing, as well as systems for testing chromatography columns.
Through the ARTeSYN acquisition in 2020, the company’s patent portfolio includes exo-technology, valves, integrated sensors, and integrated flow path systems. The company also has multiple patent grants pertaining to its single-use replacement valves and liners used in combination with its modular configurable encapsulated flow systems to provide sterilized flow paths for various bioprocessing applications.
Through the Tantti acquisition in 2024, the company’s patent portfolio includes macroporous resin and microcarrier structures; these products permit alternative chromatography solutions by offering convective mass transport.
Process Analytics
Through the company’s 2019 acquisition of C Technologies, Inc. (‘C Technologies’), it holds patent grants to various slope spectroscopy instruments, including interactive variable pathlength devices and related methods of use. C Technologies’ scientists are continually developing new analytical tools using its state-of-the-art slope spectroscopy technology, for which the company continues to file patent applications.
Proteins
The company holds a patent grant for ‘Nucleic Acids Encoding Recombinant Protein A,’ which claims sequences that encode a truncated recombinant Protein A but are otherwise identical to the natural Protein A, which is used for bioprocessing applications.
Pursuant to the company’s collaboration with Navigo, it also has multiple patent grants and multiple pending patent applications globally covering Protein A-based affinity ligands through its collaboration with Navigo. These include ligands for antibody purification, as well as ligands for purifying COVID-19 vaccines.
In addition, following the acquisition of Avitide in September 2021, the company continues to file multiple patent applications globally covering affinity ligands.
Trademarks
The company procures and maintains trademark registrations globally for the Repligen trademark and its various product brands. It prioritizes its ‘housemarks’ (e.g., Repligen, the stylized ‘R’ logo, Spectrum, TangenX, C Technologies, ARTeSYN, Polymem, Avitide, Metenova, etc.) and ensures continued protection globally. The company also has trademark registrations for various product lines, including OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, FlowVPX, RPM, XO, and AVIPure, that provide valuable company recognition and goodwill with its customers.
Licensing Agreements
The company has entered into multiple licensing and collaboration relationships with third-party business partners in an effort to fully exploit its technology and advance its bioprocessing business strategy. For example, it entered into a 15-year exclusive License Agreement with Daylight (the ‘Daylight Agreement’), giving it exclusive license and commercialization rights to use certain technology and intellectual property subject to conditions set forth in the Daylight Agreement.
Competition
The company competes with several medium and small companies in each of its product categories, as well as several large companies, including Danaher Corporation (Pall Corporation and Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma, and Sartorius.
History
Repligen Corporation was founded in 1981. The company was incorporated in 1981 under the laws of the state of Delaware.
